Health
Boehringer Aims to Challenge Astra, Bayer With Lung Cancer Pill
- Drug shows early promise in hard-to-treat patient group
- Company says study shows unprecedented efficacy, tolerability
The Boehringer Ingelheim GmbH headquarters in Ingelheim, Germany.
Photographer: Krisztian Bocsi/BloombergThis article is for subscribers only.
Boehringer Ingelheim said an early study of its oral pill for lung cancer showed promise and could potentially expand available options for a hard-to-treat patient group.
Zongertinib caused significant tumor shrinking in two-thirds of patients in the trial, with most experiencing mild and manageable effects such as diarrhea, the world’s largest private pharmaceutical company said Monday. In 3% of patients, treatment had to be discontinued due to toxicity.